Maren Nyer1, Patricia L Gerbarg2, Marisa M Silveri3, Jennifer Johnston4, Tammy M Scott5, Maya Nauphal6, Liz Owen4, Greylin H Nielsen4, David Mischoulon7, Richard P Brown8, Maurizio Fava7, Chris C Streeter9. 1. Department of Psychiatry, Harvard School of Medicine, Boston, MA, United States, United States; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States. Electronic address: mnyer@partners.org. 2. Department of Psychiatry, New York Medical College, Valhalla, NY, United States. 3. Department of Psychiatry, Harvard School of Medicine, Boston, MA, United States, United States; Department of Psychiatry, Boston University School of Medicine, Boston, MA, United States; Department of Psychiatry, McLean Hospital, Belmont, MA, United States. 4. Department of Psychiatry, Boston University School of Medicine, Boston, MA, United States. 5. Department of Psychiatry, Boston University School of Medicine, Boston, MA, United States; Department of Psychiatry, Boston Medical Center, Boston, MA, United States; Tufts University School of Medicine, Department of Psychiatry, Friedman School of Nutrition Science and Policy, Boston, MA, United States; Tufts Medical Center, Department of Psychiatry, Boston, MA, United States. 6. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States. 7. Department of Psychiatry, Harvard School of Medicine, Boston, MA, United States, United States; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States. 8. Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, United States. 9. Department of Psychiatry, Harvard School of Medicine, Boston, MA, United States, United States; Department of Psychiatry, Boston University School of Medicine, Boston, MA, United States; Department of Psychiatry, Boston Medical Center, Boston, MA, United States; Department of Neurology, Boston University School of Medicine, Boston, MA, United States; Department of Psychiatry, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, United States.
Abstract
BACKGROUND:Yoga interventions offer promise for the treatment of major depressive disorder (MDD), yet their safety and potential impact on suicidal ideation (SI) have not been well documented. This study evaluated the safety of a randomized controlled dose-finding trial of Iyengar yoga plus coherent breathing for individuals with MDD, as well as the potential effects of the intervention on SI without intent. METHODS:Participants with Beck Depression Inventory-II (BDI-II) scores ≥14 and a diagnosis of MDD (using DSM-IV criteria) were randomized to either a low dose group (LDG) or high dose group (HDG) and received a 12-week manualized intervention. The LDG included two 90-min yoga classes plus three 30-min homework sessions weekly. The HDG offered three 90-min classes plus four 30-min homework sessions weekly. RESULTS:Thirty-two individuals with MDD were randomized, of which 30 completed the protocol. At screening, SI without intent was endorsed on the BDI-II by 9 participants; after completing the intervention, 8 out of 9 reported resolution of SI. There were 17 adverse events possibly-related and 15 definitely-related to the intervention. The most common protocol-related adverse event was musculoskeletal pain, which resolved over the course of the study. CONCLUSIONS: The Iyengar yoga plus coherent breathing intervention was associated with the resolution of SI in 8 out of 9 participants, with mild side effects that were primarily musculoskeletal in nature. This preliminary evidence suggests that this intervention may reduce SI without intent and be safe for use in those with MDD.
RCT Entities:
BACKGROUND: Yoga interventions offer promise for the treatment of major depressive disorder (MDD), yet their safety and potential impact on suicidal ideation (SI) have not been well documented. This study evaluated the safety of a randomized controlled dose-finding trial of Iyengar yoga plus coherent breathing for individuals with MDD, as well as the potential effects of the intervention on SI without intent. METHODS:Participants with Beck Depression Inventory-II (BDI-II) scores ≥14 and a diagnosis of MDD (using DSM-IV criteria) were randomized to either a low dose group (LDG) or high dose group (HDG) and received a 12-week manualized intervention. The LDG included two 90-min yoga classes plus three 30-min homework sessions weekly. The HDG offered three 90-min classes plus four 30-min homework sessions weekly. RESULTS: Thirty-two individuals with MDD were randomized, of which 30 completed the protocol. At screening, SI without intent was endorsed on the BDI-II by 9 participants; after completing the intervention, 8 out of 9 reported resolution of SI. There were 17 adverse events possibly-related and 15 definitely-related to the intervention. The most common protocol-related adverse event was musculoskeletal pain, which resolved over the course of the study. CONCLUSIONS: The Iyengar yoga plus coherent breathing intervention was associated with the resolution of SI in 8 out of 9 participants, with mild side effects that were primarily musculoskeletal in nature. This preliminary evidence suggests that this intervention may reduce SI without intent and be safe for use in those with MDD.
Authors: Chris C Streeter; Patricia L Gerbarg; Richard P Brown; Tammy M Scott; Greylin H Nielsen; Liz Owen; Osamu Sakai; Jennifer T Sneider; Maren B Nyer; Marisa M Silveri Journal: J Altern Complement Med Date: 2020-01-14 Impact factor: 2.579